Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
Sweden
In shortXvivo Perfusion Aktiebolag is profitable, generates cash and holds more cash than debt, with revenue growing (+43.9% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 0.7% | 19/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 15.4% | 81/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 5.4% | 27/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 0.2% | 1/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 6.14× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.02× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 0.09× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 10.41 | 100/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 0.5% | 22/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.04× | 0/100 |
| Years with positive free cash flow (last 5) | 3 of 5 | 50/100 |
Weight in the score: 20%
| Profitable years (last 5) | 4 of 5 | 80/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 4 | 58/100 |
| Revenue growth volatility | 34.9% | 0/100 |
| Operating margin volatility | 11.6% | 4/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 49.2% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2023 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
The last 5 fiscal years from the company's annual reports.
SEK millions; negative values in parentheses.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 |
|---|---|---|---|---|---|
| Revenue | 221 | 180 | 258 | 415 | 598 |
| Cost of revenue | 58 | 50 | 70 | 118 | 152 |
| Gross profit | 163 | 130 | 188 | 297 | 445 |
| Research & development | 63 | 67 | 54 | 69 | 136 |
| Operating income | 3.9 | (46) | (18) | 6.4 | 4.2 |
| Interest expense | 0.3 | 12 | 20 | 56 | 46 |
| Pre-tax income | 5.3 | (57) | 6.7 | 22 | 95 |
| Income tax | 0.4 | (14) | (1.5) | 3.9 | 2.7 |
| Net income | 4.9 | (44) | 8.2 | 18 | 92 |
| Diluted EPS | kr0.18 | −kr1.60 | kr0.28 | kr0.62 | kr3.07 |
| Diluted shares (millions) | 27 | 27 | 29 | 30 | 30 |
10.41 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2023 · Data updated Dec 31, 2023